Retatrutide attracts substantial interest in GLP-related discussions. This guide separates established findings, investigational research, and claims that should be approached cautiously.
What is retatrutide?
Retatrutide is an investigational medicine developed by Eli Lilly. It activates three hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. That makes it different from semaglutide, which targets GLP-1, and tirzepatide, which targets GIP and GLP-1. The term “GLP-3” is an informal nickname and is not a scientifically accurate drug class.
Is retatrutide FDA approved?
No, as of October 24, 2026. Lilly describes retatrutide as investigational and in Phase 3 clinical development. Trial results are important research findings, not permission to sell or prescribe an unapproved medication to the public. Approval depends on regulatory review and could change after this page’s update.
What have trials studied?
Lilly’s Phase 3 program has examined obesity, type 2 diabetes and other weight-related conditions. Company announcements in 2026 reported substantial average weight reductions in specific trial groups. Results depend on population, protocol, duration and other factors. A figure from a clinical trial should not be used as a prediction of an individual’s results.
When reading research, look for whether the result is a company press release, a full peer-reviewed paper, or a regulatory decision. Examine the number of participants, comparison group, study duration, adverse-event findings and whether the results have been replicated.
Can you buy retatrutide online?
Retatrutide is not an FDA-approved consumer medicine. The FDA says it cannot be used in compounding under federal law and has warned companies marketing unapproved retatrutide. Offers describing it as “pharmaceutical grade,” “GLP-3,” or a “research” product should not be confused with an approved prescription medicine. We do not provide sources, self-administration instructions or dosing for investigational drugs.
How is it different from approved weight-management medicines?
Semaglutide, tirzepatide and other active ingredients have different receptor activity, formulations and regulatory status. The appropriate comparison is not just which headline reports a larger percentage of weight loss. Safety evidence, approved indication, access and individual clinical circumstances all matter. Our semaglutide vs tirzepatide comparison covers two established ingredients.
How can community members discuss the science productively?
- Link to the original study, official trial record or regulatory announcement.
- State whether findings are preliminary, published or reviewed by regulators.
- Distinguish a personal anecdote from clinical evidence.
- Do not turn trial protocols into informal treatment advice.
- Report misleading advertising and undisclosed promotion.
For open discussion, visit GLP Medications & Research. For the broader terminology, see our brand and chemical name glossary.
Continue exploring: All GLP-1 guides · Beginner’s guide · Community discussions · Ask a question
Editorial note: Updated October 24, 2026. Information is for general education, not individualized medical advice. Medication approvals and labeling can change; check current FDA labeling and consult a qualified clinician.